弥漫性大B细胞淋巴瘤（DLBCL）是淋巴瘤中最常见的亚型。它是一个高度异质性的淋巴肿瘤，具有基因表达谱和遗传变异的差异。MYD88和TP53基因在DLBCL患者中常常表达和突变，其在预后和存活中的作用存在争议。本研究旨在确定MYD88和TP53基因突变在DLBCL中的预测和预后作用。采用前瞻性队列研究方法，对50例确诊DLBCL患者和30名健康个体进行了研究，评估了MYD88和TP53基因突变的敏感性和特异性。与国际预后指数相比，突变的MYD88和TP53对预测总体死亡率和疾病进展具有更高的敏感性、特异性和准确性。突变的MYD88和TP53显示了其对较差的目标反应率和生存结局的预后重要性。突变的MYD88和TP53都与较差的ORR相关。对于MYD88和TP53而言，2年PFS和2年OS率的差异具有显著统计学意义。因此，突变的MYD88和TP53均可用于预测疾病进展和总体死亡率。© 2023. 作者。

Diffuse large B cell lymphoma (DLBCL) is the most common subtype of lymphoma. It is a highly heterogeneous lymphoid neoplasm, with variations in gene expression profiles and genetic alterations. MYD88 and TP53 genes are common to be expressed and mutated in DLBCL patients with controversy regarding their role in prognosis and survival. This study aims to determine the predictive and prognostic role of MYD88 and TP53 gene mutation in DLBCL. A prospective cohort study was conducted on 50 patients who were diagnosed with DLBCL and 30 healthy individuals to assess the sensitivity and specificity of MYD88 and TP53 genetic mutations. MYD88 and TP53 gene mutations were more sensitive, specific, and accurate in predicting overall mortality and disease progression in comparison with the international prognostic index. Mutant MYD88 and TP53 showed their prognostic importance for worse objective response rates and survival outcomes. Both mutant MYD88 and TP53 were associated with worse ORR. There was a significant statistical difference for both MYD88 and TP53 with regard to 2-year PFS and 2-year OS rate. Hence, both mutant MYD88 and TP53 can be used in predicting disease progression and overall mortality.© 2023. The Author(s).